Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-26-000064
Filing Date
2026-05-07
Accepted
2026-05-07 16:12:02
Documents
72
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20260331.htm   iXBRL 10-Q 1244548
2 EX-10.1 exhibit101outsidedirectorc.htm EX-10.1 54436
3 EX-10.2 exhibit102denali_royaltyph.htm EX-10.2 405032
4 EX-31.1 exhibit311q12026.htm EX-31.1 9891
5 EX-31.2 exhibit312q12026.htm EX-31.2 9911
6 EX-32.1 exhibit321q12026.htm EX-32.1 5550
7 EX-32.2 exhibit322q12026.htm EX-32.2 5679
  Complete submission text file 0001714899-26-000064.txt   6430949

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20260331.xsd EX-101.SCH 42677
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20260331_cal.xml EX-101.CAL 55832
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20260331_def.xml EX-101.DEF 172535
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20260331_lab.xml EX-101.LAB 550323
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20260331_pre.xml EX-101.PRE 379513
76 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20260331_htm.xml XML 681130
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 26953388
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)